Clinical trial
P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In…
NCT00390845 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00390845 |
|---|---|
| Title | P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain |
| Official title | A Double-blind Placebo-controlled Study of the Efficacy and Safety of the P38 Map Kinase Inhibitor SB681323 in Patients With Neuropathic Pain Following Nerve Trauma |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pain, Neuropathic |
| Intervention type | Drug |
| Interventions | SB681323, Placebo |
| Enrollment | 50 |
| Start date | Aug 30, 2006 |
| Primary completion | Aug 11, 2008 |
| Completion | Aug 11, 2008 |
| First posted | Oct 20, 2006 |
| Last update posted | Aug 22, 2017 |
| Countries | Australia, Germany, Russia, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: